PT  - JOURNAL ARTICLE
AU  - Desye Gebrie
AU  - Desalegn Getnet
AU  - Tsegahun Manyazewal
TI  - Cardiovascular safety and efficacy of combination therapy with metformin and sodium-glucose cotransporter-2 inhibitors versus metformin and sulfonylureas in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
AID  - 10.1101/2020.04.24.20077917
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.24.20077917
4099  - http://medrxiv.org/content/early/2020/04/29/2020.04.24.20077917.short
4100  - http://medrxiv.org/content/early/2020/04/29/2020.04.24.20077917.full
AB  - Background Diabetes mellitus is a serious threat to global health and among the top 10 causes of death, with nearly half a billion people living with it worldwide. Treating patients with diabetes tend to become more challenging due to the nature of the disease. The role and benefits of combination therapies for the management of type 2 diabetes are well-documented, while the comparative safety and efficacy among the different combination options have not been elucidated. We aimed to systematically synthesize the evidence on the comparative cardiovascular safety and efficacy of combination therapy with metformin and sodium-glucose cotransporter-2 inhibitors versus metformin and sulfonylureas in patients with type 2 diabetes.Method We searched MEDLINE-PubMed, Embase, Cochrane Library, and ClinicalTrials.gov up to 15 August 2019 and without restriction in the year of publication. We included randomized controlled trials of patients with type 2 diabetes who were on metformin- sodium-glucose cotransporter-2 inhibitors or metformin-sulphonylureas combination therapy at least for a year. The primary endpoints were all-cause mortality and serious adverse events, and the secondary endpoints were cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke, hypoglycemia, and changes in glycosylated hemoglobin A1C, body weight, fasting plasma glucose, blood pressure, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol. Random effect model was carried out to calculate mean differences for continuous outcomes and risk ratio for dichotomous outcomes between the two combination therapies.Results Of 3,190 citations, we included nine trials involving 10,974 participants. The pooled analysis showed no significance difference in all-cause mortality (RR = 0.93, 95% CI [0.52, 1.67]), serious adverse events (RR=0.96, 95% CI [0.79, 1.17]) and adverse events (RR=1.00, 95% CI [0.99, 1.02]) between the two, but in hypoglycemia (RR= 0.13, 95% CI [0.10, 0.17], P<0.00001). Participants taking metformin-sodium-glucose cotransporter-2 inhibitors showed a significantly greater reduction in HbA1c (MD= −0.10, 95% CI [−0.17, −0.03] %, body weight (MD= −4.57, 95% CI [−4.74, −4.39] kg, systolic blood pressure (MD=-4.77, 95% CI [−5.39, −4.16] mmHg, p<0.00001), diastolic blood pressure (MD=-2.07, 95% CI [−2.74, −1.40] mmHg, and fasting plasma glucose (MD= −0.55, 95% CI [−0.69, −0.41] mmol/L, p < 0.00001).Conclusion A combination therapy of metformin and sodium-glucose cotransporter-2 inhibitors is a safe and efficacious alternative to combination therapy of metformin and sulphonylureas for patients with type 2 diabetes who are at risk of cardiovascular comorbidity. However, there remains a need for additional long-term randomized controlled trials as available studies are very limited and heterogeneous.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data are within the manuscript and its supporting information files.AEsAdverse EventsAMIAcute Myocardial InfractionCADCoronary Artery DiseaseCAOCoronary Artery OcclusionCVDCardiovascular DiseaseDBPDiastolic Blood PressureFPGFasting Plasma GlucoseGMIGenital Mycotic InfectionHbA1CHemoglobin A1CHDL-CHigh Density Lipoprotein CholesterolLDL-CLow Density Lipoprotein CholesterolMDMean DifferenceMIMyocardial InfractionRCTRandomized Controlled TrialsRRRisk RatioSAEsSerious Adverse EventsSBPSystolic Blood PressureSGLT2ISodium Glucose Co-transporter 2 InhibitorT2DMType 2 Diabetes Mellitus